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Relating clinical symptoms to neuroanatomical proﬁles of brain damage and ultimately to tissue pathology is a key challenge in
the ﬁeld of neurodegenerative disease and particularly relevant to the heterogeneous disorders that comprise the frontotemporal
lobar degeneration spectrum. Here we present a retrospective analysis of clinical, neuropsychological and neuroimaging (volu-
metric and voxel-based morphometric) features in a pathologically ascertained cohort of 95 cases of frontotemporal lobar
degeneration classiﬁed according to contemporary neuropathological criteria. Forty-eight cases (51%) had TDP-43 pathology,
42 (44%) had tau pathology and ﬁve (5%) had fused-in-sarcoma pathology. Certain relatively speciﬁc clinicopathological
associations were identiﬁed. Semantic dementia was predominantly associated with TDP-43 type C pathology; frontotemporal
dementia and motoneuron disease with TDP-43 type B pathology; young-onset behavioural variant frontotemporal dementia
with FUS pathology; and the progressive supranuclear palsy syndrome with progressive supranuclear palsy pathology.
Progressive non-ﬂuent aphasia was most commonly associated with tau pathology. However, the most common clinical syn-
drome (behavioural variant frontotemporal dementia) was pathologically heterogeneous; while pathologically proven Pick’s
disease and corticobasal degeneration were clinically heterogeneous, and TDP-43 type A pathology was associated with similar
clinical features in cases with and without progranulin mutations. Volumetric magnetic resonance imaging, voxel-based morph-
ometry and cluster analyses of the pathological groups here suggested a neuroanatomical framework underpinning this clinical
and pathological diversity. Frontotemporal lobar degeneration-associated pathologies segregated based on their cerebral atrophy
proﬁles, according to the following scheme: asymmetric, relatively localized (predominantly temporal lobe) atrophy (TDP-43
type C); relatively symmetric, relatively localized (predominantly temporal lobe) atrophy (microtubule-associated protein tau
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(corticobasal degeneration, fused-in-sarcoma pathology). TDP-43 type A pathology was associated with substantial individual
variation; however, within this group progranulin mutations were associated with strongly asymmetric, distributed hemispheric
atrophy. We interpret the ﬁndings in terms of emerging network models of neurodegenerative disease: the neuroanatomical
speciﬁcity of particular frontotemporal lobar degeneration pathologies may depend on an interaction of disease-speciﬁc and
network-speciﬁc factors.
Keywords: frontotemporal dementia; frontotemporal lobar degeneration; voxel-based morphometry; MRI; neural network
Abbreviations: FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration; FTLD-U = FTLD with
ubiquitin-positive inclusions; MND = motoneuron disease; PNFA = progressive non-ﬂuent aphasia
Introduction
A central and difﬁcult issue in the neurodegenerative brain dis-
eases concerns the correspondence between phenotypic features
and microscopic and molecular pathology (Weintraub and
Mesulam, 2009). This issue has important implications for under-
standing disease neurobiology, for clinical diagnosis, and ultim-
ately, for development and rational use of disease-modifying
therapies. Such considerations are particularly pertinent to fronto-
temporal lobar degeneration (FTLD): a genetically and pathologic-
ally heterogeneous group of disorders that collectively constitute a
common cause of dementia, particularly in younger age groups
(Cairns et al., 2007a; Mackenzie et al., 2010). FTLD is a
macro-anatomical descriptive term referring to the relatively se-
lective atrophy of frontal and temporal lobes that characterizes
most cases. This atrophy is underpinned by diverse pathological
processes; these can be broadly classiﬁed according to the
major constituents of the cellular inclusions present [tau, TAR
DNA-binding protein 43 (TDP-43) or fused-in-sarcoma (FUS)
protein, designated FTLD-tau, FTLD-TDP or FTLD-FUS, respective-
ly: Mackenzie et al., 2010]. A number of causative genes have
been identiﬁed, of which the genes coding microtubule-associated
protein tau (MAPT) and progranulin (GRN) are numerically the
most important. Three canonical clinical syndromes of FTLD are
described: behavioural variant frontotemporal dementia (FTD) and
two language variants, semantic dementia and progressive
non-ﬂuent aphasia (PNFA). These syndromes overlap clinically
with motoneuron disease (FTD-MND), corticobasal syndrome
and progressive supranuclear palsy syndrome (Neary et al.,
1998; Seelaar et al., 2011). There is a broad correspondence be-
tween canonical FTLD clinical syndromes and proﬁles of brain at-
rophy detected in vivo using techniques such as MRI: behavioural
variant FTD is associated with atrophy predominantly involving the
frontal, insula, anterior cingulate and anterior temporal lobes
(especially in the non-dominant hemisphere); semantic dementia,
with asymmetric atrophy predominantly involving the anterior in-
ferior temporal lobes; and PNFA, with asymmetric (predominantly
dominant hemisphere) atrophy involving anterior peri-Sylvian
cortices (Seelaar et al., 2011).
The distinctive, focal nature of the clinico-anatomical entities
that comprise the FTLD spectrum has been recognized for many
years, most notably in the seminal clinical and macro-anatomical
descriptions of Arnold Pick (e.g. Pick, 1892) and early recognition
of a distinctive histopathological substrate with compact, often
rounded argyrophilic neuronal inclusions, which were subsequently
designated as ‘Pick bodies’ (Alzheimer, 1911). A resurgence of
interest in these disorders was heralded by Mesulam’s (1982) de-
scription of primary progressive aphasias, leading to an intense
international research effort devoted to FTLD and its brain correl-
ates using a range of neuropsychological, neuroimaging and
neuropathological approaches. It has recently been shown that
syndromes within the FTLD spectrum map onto large-scale brain
networks (Seeley et al., 2009), suggesting a new paradigm for
explaining the distributed and heterogeneous patterns of regional
atrophy in FTLD. Following this paradigm, the macroscopic top-
ography of network disintegration in FTLD directs the develop-
ment of clinical symptoms. However, no clinico-anatomical
formulation has been shown reliably to predict tissue pathology
across the FTLD spectrum (Weintraub and Mesulam, 2009), lead-
ing to suggestions that the diseases constitute an overlapping
complex with a collectively limited and convergent phenotypic
repertoire (Kertesz, 2010). A more fundamental problem concerns
the basis for phenotypic selectivity and regional neuronal vulner-
ability in FTLD, as in other dementias (Seeley et al., 2008, 2009;
Weintraub and Mesulam, 2009). Recent work in both sporadic
and genetically mediated forms of FTLD has suggested potential
micro-anatomical (Seeley et al., 2006) and molecular (Rohrer
et al., 2010b, e) bases for distinctive phenotypic features within
the FTLD spectrum. Furthermore, recent advances in immunophe-
notyping have transformed and expanded our histopathological
picture of FTLD (Mackenzie et al., 2010).
The normal brain contains six isoforms of tau, with either three
(3R-tau) or four (4R-tau) microtubule-binding repeats. Mutations
of the MAPT gene are associated with two patterns of abnormal
tau accumulation: mutations in the coding region outside exon
10 lead to accumulation of both 3R- and 4R-tau restricted to
neurons, while mutations in the coding region of exon 10 (or
with increased splicing of exon 10) lead to accumulation of
4R-tau in both neurons and glia. Most sporadic tauopathies
(including corticobasal degeneration and progressive supranuclear
palsy) have predominant 4R-tau deposition (Sergeant et al.,
1999); however, Pick bodies contain predominantly or exclusively
3R-tau (de Silva et al., 2006). In this article, corticobasal degen-
eration and progressive supranuclear palsy are used to refer to the
pathological entities corticobasal degeneration and progressive
supranuclear palsy, distinguished from the clinical designations of
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drome. The classiﬁcation of non-tau FTLD pathologies continues
to be reﬁned. Two nomenclature systems subtyping FTLD-TDP
based on detailed immunohistochemical and morphological
analysis are currently in use (Mackenzie et al., 2006; Sampathu
et al., 2006); recently, a scheme for harmonizing these two patho-
logical classiﬁcation systems was proposed (Mackenzie et al.,
2011), and has been adopted here. Four subtypes of FTLD-TDP
have been described: type A (TDP-A), associated in a proportion
of cases with mutations in the GRN gene; type B (TDP-B), asso-
ciated with FTD-MND; type C (TDP-C) associated predominantly
with semantic dementia; and type D (TDP-D), associated with
mutations in the valosin-containing protein (VCP) gene
(Mackenzie et al., 2010). Several pathological entities within the
non-tau spectrum but lacking TDP-43 [including cases previously
described as atypical FTLD with ubiquitin-positive inclusions
(FTLD-U), neuronal intermediate ﬁlament inclusion disease and
basophilic inclusion body disease] have recently been shown to
have predominant accumulation of FUS protein (FTLD-FUS;
Munoz et al., 2009; Neumann et al., 2009a, b; Urwin et al.,
2010; Lashley et al., 2011). Finally, a small proportion of cases
of FTLD have inclusions negative for tau, TDP-43 or FUS, includ-
ing cases associated with charged multivesicular body protein 2B
(CHMP2B) mutations (ubiquitin-positive, TDP-43- and FUS-
negative inclusions: FTLD-UPS) and others lacking inclusions
(Mackenzie et al., 2010). This capacity for enhanced immunohis-
tochemical and molecular differentiation of FTLD provides an
unprecedented opportunity to assess phenotypic associations
within the FTLD spectrum that may previously have been obscure.
Here we undertook a detailed analysis of clinical, neuropsycho-
logical and neuroimaging features in a large retrospectively ascer-
tained series of patients with pathologically conﬁrmed FTLD
attending a tertiary cognitive disorders clinic. Cases were charac-
terized using a uniform neuropathological protocol motivated by
recent advances in immunohistochemical and genetic diagnoses.
We used the complementary techniques of magnetic resonance
volumetry and voxel-based morphometry to assess neuroanatom-
ical associations of pathologically and genetically characterized dis-
ease groups. Our objectives were to identify clinical and
neuroanatomical signatures of FTLD pathologies, as deﬁned
using contemporary histopathological and molecular techniques;
and to interpret such signatures in light of the emerging paradigm
of network-mediated neurodegeneration in FTLD. Our central
hypotheses were ﬁrst, that molecular pathologies of FTLD trans-
late to identiﬁable proﬁles of large-scale brain network damage;
and secondly, that these proﬁles show speciﬁcity for particular
FTLD pathologies.
Materials and methods
We retrospectively reviewed the database of the Specialist Cognitive
Disorders Clinic at the National Hospital for Neurology and
Neurosurgery, Queen Square, London, UK for the period 1993–2009
in order to identify patients with a pathological diagnosis within the
FTLD spectrum (Cairns et al., 2007; Mackenzie et al., 2010).
Ninety-ﬁve patients were identiﬁed (90 with post-mortem; 5 with
in vivo diagnostic frontal lobe biopsy conﬁrmation). All pathological
specimens were assessed using a standard protocol and genetic, demo-
graphic, clinical, neuropsychological and neuroimaging data were ana-
lysed. Ethical approval for the study was obtained from the National
Hospital for Neurology and Neurosurgery Local Research Ethics
Committee.
Neuropathological and genetic analyses
Brain specimens were obtained from the Queen Square Brain Bank,
London and the Institute of Psychiatry, London. The samples were
ﬁxed in 10% buffered formalin for histopathology and immunohisto-
chemistry. Histological sections of representative brain regions of the
90 post-mortem cases and the ﬁve frontal cortical biopsies were
stained with haematoxylin and eosin. Immunohistochemistry was per-
formed using a panel of antibodies. Anti-tau antibodies comprised the
AT8 monoclonal antibody against tau phosphorylated at Ser 202/Thr
205 (1:600, Autogen Bioclear); RD3 against 3R-tau (1:10000,
Upstate) and RD4 monoclonal antibody against 4R-tau (1:100,
Upstate). A primary antibody was applied recognizing the TDP-43
protein at amino acids 1–261 (1:800, Abnova). FUS pathology was
recognized using the anti-FUS antibody to amino acids 1–50 (1:200,
Novus). In addition, antibodies to ubiquitin (1:200, Dako), p62
(1:200, BD Transduction Laboratories), -synuclein (1:50, Vector),
Ab (1:100, Dako) and GFAP (1:1000, Dako) were used. After the
primary antibody was applied sections were incubated with a biotiny-
lated anti-mouse (1:200, Dako) or anti-rabbit (1:200, Dako) second-
ary antibody, as appropriate. Finally, ABC (Dako) was applied and
colour was developed by diaminobenzidine/H2O2. The neuropatho-
logical diagnosis was determined using established diagnostic criteria,
in line with consensus recommendations for the FTLD spectrum and
for speciﬁc entities within the spectrum (Cairns et al., 2007;
Mackenzie et al., 2009, 2010; Munoz et al., 2009; Neumann et al.,
2009a, b). Details of histopathological ﬁndings are summarized in the
Supplementary Material.
For all post-mortem cases, additional (non-FTLD) pathological fea-
tures were determined and quantiﬁed according to standard criteria.
Quantitation of Ab-positive mature and diffuse plaques was performed
based on Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) recommendations (Lashley et al., 2008). Alzheimer-type
neuroﬁbrillary tangle pathology was determined using AT8 immuno-
histochemistry for Braak staging (Braak et al., 2006). The extent and
severity of cerebral amyloid angiopathy was determined based on a
four-tier grading system (Olichney et al., 1996; Lashley et al., 2008).
The presence of cerebrovascular pathology was examined in the front-
al lobe, basal ganglia and pons using a previously described approach
(Williams et al., 2007). This included atherosclerosis, lipohyalinosis,
micro-aneurysm and arteriolosclerosis and their sequelae, such as
lacunes and perivascular rarefaction. Vascular pathology was graded
as mild (occasional vessels affected), moderate (a signiﬁcant proportion
of the small vessels affected with few or no sequelae noted) or severe
(a signiﬁcant proportion of the small vessels affected with obvious
sequelae).
All patients with available DNA (n = 71) were screened for known
mutations in progranulin (GRN), microtubule-associated protein tau
(MAPT), valosin-containing protein (VCP), fused-in-sarcoma (FUS),
TAR DNA-binding protein (TARDP) and charged multivesicular body
protein 2B (CHMP2B) genes as part of a previous study (for details see
Rohrer et al., 2009). The GRN 30 untranslated region rs5848 geno-
type, reported as a risk factor for FTLD-TDP (Rademakers et al., 2008)
had also been assessed in all cases with DNA as part of a previous
study (Rollinson et al., 2011).
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Clinical diagnosis in each patient was based upon a structured review
of the clinical history and examination ﬁndings as recorded in the case
ﬁle. Consensus criteria were followed (Litvan et al., 1996; Neary et al.,
1998; Boeve et al., 2003). Neuropsychological assessments were re-
viewed and data extracted for relevant cognitive measures
(Supplementary Material).
Neuroimaging analysis: volumetric data
Forty-two patients [26 males, mean age at scan 60.0 (SD 8.8) years]
had volumetric magnetic resonance brain imaging performed on a
1.5T GE Signa scanner (General Electric). Magnetic resonance brain
images were also acquired for 35 age-matched cognitively normal
control subjects [16 males, mean age at scan 63.7 (SD 7.0) years].
Whole brain and cerebral hemisphere volumes were calculated in all
individuals as previously described (Rohrer et al., 2010e), and an index
of cerebral asymmetry was derived [(absolute hemispheric volume dif-
ference/whole brain volume   100)]. Volumetric analysis of grey
matter cortical and subcortical (hippocampus, amygdala, caudate,
putamen and brainstem) areas was performed using the Freesurfer
image analysis suite (version 4.0.3; http://surfer.nmr.mgh.harvard.
edu/), on a 64-bit Linux CentOS 4 Sun Grid Engine Cluster. These
brain regions were selected on the basis they were likely a priori to be
targeted by pathologies in the FTLD spectrum.
Regional volumetric data for each patient were analysed statistically
using STATA 10.0 (Stata Corporation). Individual regional brain
sub-volumes were calculated as the mean of left and right volume
values for each region and corrected for total intracranial volume.
Linear regression with 95% bias-corrected bootstrap conﬁdence inter-
vals and 1000 replicates was used to assess for differences in total
intracranial volume-corrected brain sub-volumes between disease
groups and controls, and between disease groups. Logistic regression
was used to explore associations between neuroimaging parameters
and pathological diagnosis. Each pathological diagnosis with available
MRI data was assessed in turn and the relationship of each diagnosis
with regional brain volumes and with cerebral asymmetry index was
compared with all other pathological diagnoses. For each diagnostic
group, parameters showing signiﬁcant differences (P50.05) in uni-
variate analyses were then entered into a multivariate reverse stepwise
model.
Neuroimaging analysis: group-level
voxel morphometry data
Voxel-based morphometry was undertaken to assess group-level
changes associated with pathological diagnoses relative to the healthy
control group. Brain images were entered into the voxel-based morph-
ometry analysis using SPM5 software (http://www.ﬁl.ion.ucl.ac.uk/
spm) and the DARTEL toolbox, and grey and white matter brain seg-
ments were derived as previously described (Rohrer et al., 2010d, e).
Voxel-based morphometry is an unbiased technique that makes no
prior assumptions about the distribution of atrophy in particular dis-
eases; it can therefore be regarded as complementary to regional
volumetry. In order to capture individual hemispheric asymmetries
that might otherwise be obscured in a group voxel-based morphom-
etry analysis after mapping all brain images into a common space, we
performed the analysis on images ﬂipped from native space in the
midsagittal plane within SPM5, such that the most severely affected
cerebral hemisphere was on the same side in each patient. This pro-
cedure ensured that any group-level asymmetry of atrophy (whether
atrophy was predominantly left- or right-ward directed in individual
subjects) would be evident in the group analysis. An individual image
was selected for ﬂipping if it had a hemispheric asymmetry index out-
side the control range and more severe right hemisphere atrophy (i.e.
images were ﬂipped such that any asymmetric atrophy was displayed
on the left). Voxel intensity was modelled as a function of group
membership, and subject age, gender and total intracranial volume
were included as nuisance covariates. Separate analyses were per-
formed on the grey matter and white matter segments. Statistical
parametric maps were generated showing signiﬁcant differences be-
tween each pathological group and the healthy control group; these t-
statistic maps were thresholded at signiﬁcance level 0.01 (corrected for
multiple comparisons over the whole brain volume using false discov-
ery rate). Maps were displayed as overlays on a study-speciﬁc tem-
plate brain image, created by warping all native space whole-brain
images to the ﬁnal DARTEL template and calculating the average of
the warped brain images. Proximity to white matter tracts was deter-
mined by reference to a tractographic atlas (Wakana et al., 2004).
Results
Clinical and neuropathological data from the FTLD cohort are
summarized in Table 1. Considering the cohort as a whole,
42 of the 95 cases (44%) had tau pathology, comprising Pick’s
disease (n = 13), pathology consistent with MAPT mutations
(n = 14), corticobasal degeneration (n = 9) and progressive supra-
nuclear palsy (n = 6); 48 (51%) had TDP-43 pathology, compris-
ing TDP-A (n = 25), TDP-B (n = 3), TDP-C (n = 19) and TDP-D
(n = 1); and ﬁve (5%) had FUS pathology, comprising atypical
FTLD-U (n = 4) and neuronal intermediate ﬁlament inclusion dis-
ease (n = 1). Genetic analysis identiﬁed mutations in the MAPT or
GRN genes in 22 cases (23% of the series). A pathogenic muta-
tion was conﬁrmed in 13 of the 14 cases with pathology consist-
ent with a mutation in the MAPT gene: nine with 10+16 intronic
mutations, two with G389R mutations and single cases with
N296N and R406W mutations; DNA was not available in the re-
maining case. Nine of 21 TDP-A cases where DNA was available
for screening had GRN mutations: seven with C31fs, one with
Q130fs, one with 1048_1049insG. Of the remaining 12 GRN-
mutation-negative cases with available DNA, three (25%) had
the TT GRN 30 untranslated region rs5848 genotype that was ini-
tially reported to be associated with FTLD-TDP (compared with
28/347 or 8% of normal controls—no signiﬁcant difference,
P = 0.08 Fisher’s exact test); six cases (50%) had the CT genotype
(compared with 44% of controls) and three (25%) had the CC
genotype (compared with 48% of controls). Half of the cases with
TDP-A pathology but without GRN mutations also had strong
evidence of a family history: two cases had a modiﬁed Goldman
score (Rohrer et al., 2009) of one (autosomal dominant family
history of FTLD) and four had a score of two (three or more
family members with dementia). Behavioural variant FTD was
the most common clinical syndrome in the series (47/95 cases,
49%), followed by semantic dementia (23/95 cases, 24%) and
PNFA (10/95 cases, 11%). The ﬁve in vivo brain biopsy cases in
this series comprised three cases of Pick’s disease, one case with
2568 | Brain 2011: 134; 2565–2581 J. D. Rohrer et al.corticobasal degeneration and one with FUS-neuronal intermedi-
ate ﬁlament inclusion disease pathology.
Results of the quantitative analysis for coexisting pathological
features of Alzheimer’s disease and cerebrovascular disease are
presented in Supplementary Table 1. This analysis revealed that
additional pathological ﬁndings were minor in most (78/90
post-mortem) cases. No cases fulﬁlled Braak criteria correlating
with established Alzheimer’s disease based on staging of neuroﬁb-
rillary tangle pathology; three cases (one in each of the cortico-
basal degeneration, TDP-A and TDP-C groups) additionally
fulﬁlled Braak criteria correlating with ‘mild cognitive impairment’,
and two of these cases also had frequent amyloid plaques and
signiﬁcant vascular amyloid deposition. Four other cases (one
with Pick’s, two with MAPT mutations, one with progressive
supranuclear palsy pathology) showed frequent Ab amyloid pla-
ques based on CERAD criteria. Cerebrovascular pathology was
graded as moderate in four cases (one with a MAPT mutation,
one with corticobasal degeneration and two with FUS pathology)
and severe in three cases (one in each of the progressive supra-
nuclear palsy, TDP-A and TDP-C groups).
We now consider the histopathological associations of particular
clinical syndromes and of particular atrophy patterns on volumetric
MRI. We then consider the data from the complementary per-
spective of the histopathological substrates, considering the clinical
and neuroanatomical proﬁles of particular pathologies.
Clinical syndromes: histopathological
associations of clinical features
Histopathological associations of clinical and neuropsychological
features of the cases in this series are summarized below and in
the Supplementary Material.
Presentations with behavioural variant FTD were observed in
association with all pathologies except TDP-C, TDP-B (associated
with FTD-MND) and progressive supranuclear palsy
(Supplementary Table 2). Semantic dementia was associated
with TDP-C pathology in 19 of 23 cases (83%); the remaining
four patients had Pick’s disease (Supplementary Table 3), and the
presence of acalculia (not referenced in current consensus criteria
for semantic dementia: Gorno-Tempini et al., 2011) appeared to
be associated with underlying Pick’s pathology (present in three of
four patients who exhibited acalculia). PNFA was a presentation of
tau pathologies in 7 of 10 cases (70%): three patients had Pick’s
disease, four had corticobasal degeneration (Supplementary
Table 4) and orofacial apraxia developed only in patients with
tau pathologies. Presentation with corticobasal syndrome was
associated with tau (corticobasal degeneration, progressive
supranuclear palsy or MAPT mutation) pathologies in four of
ﬁve cases; the remaining patient had TDP-A pathology in
association with a GRN mutation. Progressive supranuclear palsy
syndrome was associated with tau pathology in all six cases; ﬁve
patients had progressive supranuclear palsy pathology, while the
remaining patient had corticobasal degeneration pathology. FTD-
MND was associated with TDP-43 pathology in all four cases;
three patients had TDP-B pathology, and the remaining patient
had TDP-A pathology. Certain clinical features were observed
across the cardinal syndromic groups (Supplementary
Tables 2–4). Behavioural symptoms commonly developed in the
course of the aphasic syndromes and in general did not discrim-
inate between histopathological substrates. Other common fea-
tures were episodic memory impairment, executive dysfunction
and anomia. Visuospatial impairment and limb apraxia were not
observed in association with MAPT mutations, TDP-C or FUS
pathologies.
Table 1 Pathological and clinical summary of cases in the series
Pathology n (%) Gender,
% male
Age at
clinical
onset,
mean
(SD)
(years)
Age at
death,
mean
(SD)
(years)
Duration,
mean
(SD)
(years)
Clinical presentation
Behavioural
variant FTD
FTD/MND Semantic
dementia
PNFA Corticobasal
syndrome
PSPS
Tau 42 (44)
Pick’s disease 13 (14) 69.2 55.4 (5.8) 69.2 (3.5)
a 12.0 (4.3)
a 60 4 3 0 0
MAPT mutations 14 (15) 64.3 50.4 (8.6) 62.6 (10.4) 12.1 (4.3) 12 0 0 0 2 0
Corticobasal degeneration 9 (9) 55.6 58.2 (9.0) 67.8 (7.8)
b 8.3 (2.2)
b 30 0 4 1 1
Progressive supranuclear palsy 6 (6) 28.6 59.0 (5.2) 69.8 (36) 10.0 (1.9) 0 0 0 0 1 5
TDP-43 48 (51)
A 25 (26)
(9 GRN)
60.0 58.3 (6.9) 65.3 (8.2) 6.4 (2.5) 20 1 0 3 1 0
B 3 (3) 33.3 55.7 (6.7) 60.8 (5.7) 5.2 (1.0) 0 3 0 0 0 0
C 19 (20) 78.9 59.3 (6.6) 72.2 (5.9) 12.9 (2.7) 0 0 19 0 0 0
D 1 (1) 100.0 52.0 62.0 10.0 1 0 0 0 0 0
FUS 5( 5 )
Atypical FTLDU 4 (4) 100.0 45.5 (4.7) 53.9 (4.4) 8.4 (2.5) 4 0 0 0 0 0
NIFID 1 (1) 0.0 27.0 NA NA 1 0 0 0 0 0
TOTAL 95 47 4 23 10 5 6
a Data from 10 patients.
b Data from 8 patients.
NA = not available; NIFID = neuronal intermediate ﬁlament inclusion disease; PSPS = progressive supranuclear palsy syndrome.
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ﬁndings: neuroimaging predictors of
tissue pathology
Volumetric data for different pathological groups are presented in
Table 2 and Fig. 1. The pathological groups with neuroimaging
data were Pick’s disease (n = 9), MAPT mutations (n = 6), cortico-
basal degeneration (n = 5), TDP-A (n = 7; four with GRN muta-
tions), TDP-C (n = 12) and FUS pathology (two cases with atypical
FTLD-U, one with neuronal intermediate ﬁlament inclusion dis-
ease). Regional volumetric data were not available for one case
in the TDP-A group; the small FUS group was excluded from
logistic regression analyses.
In univariate logistic regression analyses (thresholded at signiﬁ-
cance level P50.05), Pick’s disease was associated with smaller
mean putaminal and frontal lobe volumes, and greater hemispher-
ic asymmetry; MAPT mutations with less hemispheric asymmetry;
corticobasal degeneration with larger mean hippocampal, amyg-
dala and temporal lobe volumes and with less hemispheric asym-
metry (last association borderline signiﬁcant, P = 0.066); TDP-C
pathology with larger mean putaminal, cingulate and frontal
lobe volumes and with smaller mean temporal lobe volume (last
association borderline signiﬁcant, P = 0.069); and TDP-A path-
ology with smaller cingulate volume (borderline signiﬁcant,
P = 0.054).
In multivariate analyses (all thresholded at signiﬁcance level
P50.05), Pick’s disease was associated with the combination of
smaller putaminal volume with greater hemispheric asymmetry;
MAPT mutations with less hemispheric asymmetry; corticobasal
degeneration with the combination of larger hippocampal
volume with less hemispheric asymmetry; and TDP-C with the
combination of smaller temporal lobe volume with larger frontal
lobe volume.
Histopathological substrates: clinical
proﬁles of tissue pathology
Pick’s disease
In the 13 patients with Pick’s disease, the initial clinical syndrome
was behavioural variant FTD in six cases, PNFA in three cases and
semantic dementia in four cases. Cases with semantic dementia on
the basis of Pick’s disease were more likely to have acalculia
than cases with semantic dementia with TDP-C pathology
(Supplementary Table 3). Asymmetric limb apraxia (more severe
contralateral to the maximally atrophic hemisphere) in keeping
with corticobasal syndrome developed subsequently in two pa-
tients presenting with behavioural variant FTD and one presenting
with PNFA. Parkinsonism developed in two patients. Unexplained
episodes of sudden collapse with loss of consciousness developed
in two patients, and one patient reported an alteration of visual
perception (washes of red over the visual scene without formed
visual hallucinations). Certain features became prominent later in
the disease course for the Pick’s disease group as a whole: pro-
gressive reduction in spontaneous speech leading to mutism
Table 2 Volumetric imaging data for different pathological groups in FTLD cohort
Pick’s
disease
MAPT
mutations
Corticobasal
degeneration
TDP-A TDP-C FUS-atypical
FTLDU
No. of cases 9 6 5 7 12 2
Disease duration at scan, mean (SD) (years) 4.7 (1.7) 5.1 (2.4) 4.4 (0.8) 3.8 (2.0) 4.6 (2.4) 3.6 (2.9)
Total brain volume (% control mean) 88 (10)* 94 (9) 85 (6)* 86 (10)* 94 (8)* 89 (4)*
Cerebral asymmetry index
a 4.3 (2.4)* 1.2 (0.8)* 1.3 (0.5)* 3.4 (2.7)* 3.0 (1.0)* 1.6 (0.7)*
Grey matter lobar volume (% control mean)
Frontal 73 (14)* 92 (10) 81 (14)* 73 (11)* 95 (12) 69 (6)*
Temporal 73 (11)* 73 (7)* 87 (17) 76 (15)* 69 (11)* 81 (5)*
Parietal 88 (10)* 89 (11)* 85 (20) 82 (10)* 94 (14) 88 (11)*
Cingulate 70 (15)* 88 (18)* 82 (11)* 65 (7)* 89 (18)* 75 (16)*
Subcortical volumes (% control mean)
Hippocampus 67 (18)* 57 (3)* 86 (16) 77 (27)* 67 (17)* 69 (3)*
Amygdala 55 (21)* 50 (11)* 80 (19)* 75 (23)* 53 (16)* 63 (3)*
Caudate 77 (12)* 87 (12)* 85 (6)* 86 (18) 89 (11)* 66 (19)*
Putamen 62 (12)* 75 (9)* 76 (11)* 75 (9)* 81 (12)* 67 (17)*
Brainstem 97 (11) 95 (10) 91 (13) 94 (11) 99 (7) 92 (19)
Only a single FUS-neuronal intermediate ﬁlament inclusion disease case was identiﬁed and so was not included in the table.
a Calculated as follows: (absolute hemispheric volume difference/whole brain volume   100).
*Signiﬁcantly different to controls, P50.05; signiﬁcant volume differences between disease groups (P50.05) follow.
Total brain volume: corticobasal degeneration5TDP-C. Asymmetry index: Pick’s disease4MAPT mutations, corticobasal degeneration, TDP-C, FUS-atypical FTLD-U;
TDP-A4MAPT mutations, corticobasal degeneration; TDP-C4MAPT mutations, corticobasal degeneration, FUS-atypical FTLD-U. Frontal lobe: Pick’s disease5MAPT
mutations, TDP-C; TDP-A5MAPT mutations, TDP-C; FUS-atypical FTLD-U5MAPT mutations, TDP-C. Temporal lobe: TDP-C5corticobasal degeneration, FUS-atypical
FTLD-U. Parietal lobe: TDP-A5TDP-C. Cingulate: Pick’s disease5TDP-C; TDP-A5MAPT mutations, corticobasal degeneration, TDP-C. Hippocampus: Pick’s dis-
ease5corticobasal degeneration; MAPT mutations5corticobasal degeneration, TDP-C; TDP-C5corticobasal degeneration. Amygdala: Pick’s disease5corticobasal
degeneration; MAPT mutations5corticobasal degeneration; TDP-C5corticobasal degeneration. Caudate: Pick’s disease5TDP-C; FUS-atypical FTLD-U5TDP-C.
Putamen: Pick’s disease5MAPT mutations, corticobasal degeneration, TDP-A, TDP-C.
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and impaired single word comprehension developed in the
majority.
MAPT mutations
Twelve of the 14 patients in the MAPT mutation group presented
with behavioural variant FTD; the remaining cases presented with
corticobasal syndrome. These cases have been previously reported
(Rohrer et al., 2009). All patients (including the nine cases with
10+16 intronic mutations) presenting with behavioural variant
FTD syndrome had prominent disinhibition and developed seman-
tic impairment with profound anomia and episodic memory im-
pairment as the disease progressed. Parkinsonism developed in ﬁve
cases.
Corticobasal degeneration
In the nine patients with corticobasal degeneration pathology, the
initial clinical syndrome was variable: three patients had behav-
ioural variant FTD, four had PNFA, one had corticobasal syndrome
and one had progressive supranuclear palsy syndrome. However,
corticobasal syndrome developed later in the course in four pa-
tients presenting with an alternative clinical syndrome (one behav-
ioural variant FTD, two PNFA and one progressive supranuclear
palsy syndrome). Most patients exhibited behavioural abnormal-
ities and all developed word-ﬁnding difﬁculty over the course of
the illness. Parkinsonism was seen in ﬁve cases.
Progressive supranuclear palsy
Progressive supranuclear palsy pathology was associated with pro-
gressive supranuclear palsy syndrome in all but one case who had
corticobasal syndrome.
TDP-A pathology
Twenty of the 25 patients with TDP-A pathology presented with
behavioural variant FTD. Of the remaining patients, three pre-
sented with PNFA, one with corticobasal syndrome and one
with FTD/MND. Excluding patients for whom no DNA was avail-
able, we compared the TDP-A subgroup with GRN mutations
(nine patients) with the subgroup lacking GRN mutations (12 pa-
tients); results are summarized in Supplementary Table 5.
Considering the neuropsychological proﬁles early in the course,
executive dysfunction was present in all patients assessed and epi-
sodic memory impairment was frequent in both subgroups, while
parietal lobe dysfunction (characterized by limb apraxia, dyscalcu-
lia or visuospatial impairment) was also common, though some-
what more frequent in the GRN mutation subgroup. The GRN-
mutation-negative patient with progressive aphasia presented with
reduced speech output and anomia without speech apraxia but
with emergence of a single word comprehension deﬁcit, consistent
with previous descriptions of GRN-related progressive aphasia
(Rohrer et al., 2010a). A similar range of behavioural symptoms
was seen in the subgroups with and without GRN mutations:
apathy was the most frequent behavioural abnormality in both
Figure 1 Cerebral interhemispheric asymmetry in FTLD pathological groups and in healthy controls. For display purposes, hemispheric
asymmetry is here expressed as the ratio of left/right hemisphere volumes for each subject. Horizontal lines indicate healthy control range
aFTLDU = atypical FTLDU; CBD = corticobasal degeneration; NIFID = neuronal intermediate ﬁlament inclusion disease.
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by patients in each subgroup.
TDP-B pathology
All patients in this group had FTD-MND presenting as a behav-
ioural syndrome with features of MND supervening later in the
course. All patients exhibited disinhibition, apathy, loss of em-
pathy, perseverative or obsessional behaviours and appetite
changes, and one patient had prominent delusions (Omar et al.,
2009). This group had the shortest mean clinical disease duration
[5.2 (SD 1.0) years] of the entire FTLD cohort.
TDP-C pathology
All patients in this group presented with semantic dementia. This
group had the longest mean clinical disease duration [12.9 (SD
2.7) years] of the entire FTLD cohort.
TDP-D pathology
A single patient was found to have TDP-D pathology although
DNA was not available for genetic analysis. He developed progres-
sive muscle weakness (diagnosed as ‘spinal muscular atrophy’) at
the age of 49 years, followed 3 years later by progressive behav-
ioural and cognitive impairment. His brother also had a diagnosis
of ‘spinal muscular atrophy’ with onset in his 50s, his sister had
been diagnosed with dementia in her 50s and his mother had died
of ‘dementia’ aged 55 years. Neuropsychological assessment six
years after the onset of cognitive impairment revealed anomia,
dyslexia, dysgraphia and dyscalculia with relatively intact episodic
memory and right hemisphere functions. Neurological examination
at this time revealed bilateral facial weakness and proximal limb
weakness. Brain CT revealed asymmetrical atrophy maximally af-
fecting the left cerebral hemisphere.
FUS pathology
All patients with FUS pathology presented with behavioural variant
FTD. The single patient with neuronal intermediate ﬁlament
inclusion disease had dysarthria and limb apraxia, while the four
patients with atypical FTLD-U had a normal neurological examin-
ation. This group had the earliest clinical onset of the entire FTLD
cohort [atypical FTLD-U, mean age at onset 45.5 (SD 4.7) years;
neuronal intermediate ﬁlament inclusion disease, age at onset 27
years]. These ﬁve patients have been described previously (Rohrer
et al., 2010c).
Histopathological substrates:
neuroanatomical proﬁles of tissue
pathology
Volumetric magnetic resonance imaging proﬁles
Particular tissue pathologies were associated with distinctive
proﬁles of regional brain atrophy relative to healthy controls
(summarized in Table 2). Pick’s disease was associated with asym-
metric, predominantly frontal and temporal lobe atrophy with
additional severe involvement of cingulate and putamen. MAPT
mutations were associated with largely symmetric, predominantly
temporal lobe atrophy. Corticobasal degeneration was associated
with symmetric, rather diffuse atrophy, accentuated in the frontal
lobes but with wide individual variation. TDP-C was associated
with asymmetric atrophy predominantly involving the temporal
lobes. TDP-A was associated with asymmetric atrophy with a
frontal emphasis but extending rather diffusely within the more
affected hemisphere to involve the parietal lobe and with marked
involvement of the cingulate. Within the TDP-A group, the most
asymmetric interhemispheric atrophy was associated with GRN
mutations. FUS-atypical FTLD-U (based on only two cases with
MRI) was associated with largely symmetric atrophy, most marked
in the frontal lobes but also involving the temporal lobes and with
severe involvement of caudate.
An important issue in FTLD concerns the extent to which neu-
roimaging features reﬂect clinical syndromes versus underlying
tissue pathologies. We therefore also consider the volumetric pro-
ﬁles associated with tissue pathologies within each of the major
syndromic groups (Supplementary Tables 2–4). Comparing
within-syndrome subgroup-level proﬁles for pathologies repre-
sented in more than one syndromic group (Pick’s, TDP-A and
corticobasal degeneration), Pick’s disease (irrespective of the clin-
ical syndrome) was consistently associated with asymmetric, pre-
dominantly frontotemporal, cingulate and putaminal atrophy and
TDP-A with asymmetric frontoparietal and cingulate atrophy,
while corticobasal degeneration was associated with more sym-
metric and more diffuse atrophy. However, there was also evi-
dence that clinical syndrome modulates the regional distribution
of atrophy: in the Pick’s disease subgroup, temporal lobe atrophy
was more marked for cases presenting with semantic dementia
than with other clinical syndromes. Conversely, within the seman-
tic dementia syndromic group, the Pick’s and the TDP-C patho-
logical groups exhibited very similar proﬁles of atrophy within the
temporal lobe but the Pick’s disease subgroup was associated with
more marked asymmetry of temporal lobe involvement and add-
itionally associated with more marked, asymmetric parietal lobe
atrophy (Supplementary Table 3).
Signiﬁcant neuroanatomical volumetric differences
between pathological groups
Disease-associated neuroanatomical proﬁles were substantiated by
direct statistical comparisons of volumetric data between the
pathological groups (all P50.05). Total brain volume was signiﬁ-
cantly smaller in the corticobasal degeneration group than the
TDP-C group. Interhemispheric cerebral asymmetry was signiﬁ-
cantly greater in the Pick’s disease, TDP-A and TDP-C groups than
the MAPT mutation, corticobasal degeneration and FUS-atypical
FTLD-U groups. Frontal lobe volume was signiﬁcantly smaller in
the Pick’s disease, TDP-A and FUS-atypical FTLD-U groups than
the MAPT mutation and TDP-C groups. Temporal lobe volume
was signiﬁcantly smaller in the TDP-C group than the corticobasal
degeneration and FUS-atypical FTLD-U groups; while hippocampal
and amygdala volume was signiﬁcantly smaller in the Pick’s,
MAPT mutation and TDP-C groups than in the corticobasal de-
generation group. Parietal lobe volume was signiﬁcantly smaller in
the TDP-A group than the TDP-C group. Cingulate volume was
signiﬁcantly smaller in the Pick’s group than the TDP-C group, and
signiﬁcantly smaller in the TDP-A group than the MAPT mutation,
corticobasal degeneration and TDP-C groups. Caudate volume
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groups than the TDP-C group. Putaminal volume was signiﬁcantly
smaller in the Pick’s group than the MAPT mutation, corticobasal
degeneration, TDP-A and TDP-C groups.
In summary, these data provide quantitative support for dis-
tinctive neuroanatomical proﬁles of pathologies in the FTLD spec-
trum. Pick’s, TDP-A and TDP-C were associated with more
marked interhemispheric asymmetry than other pathological
groups. Within an affected hemisphere, TDP-C pathology and
MAPT mutations were associated with relatively focal temporal
lobe atrophy, while other pathologies were associated with more
widespread cortical atrophy and variable involvement of subcor-
tical nuclei.
Voxel-based morphometry proﬁles
The voxel-based morphometry analysis of regional atrophy in each
of the pathological groups corroborated the results of MRI
volumetry. Representative sections showing proﬁles of tissue loss
are displayed in Figs 2 and 3, and brain regions involved are
summarized in Table 3; these analyses are based on ﬂipped
images (following the procedure described in the ‘Materials and
methods’ section), in order to capture directional asymmetries
that might be evident only at individual subject level. All re-
sults are reported with reference to the healthy control group;
direct comparisons between disease groups did not yield signiﬁ-
cant grey matter associations at the prescribed signiﬁcance
threshold.
Relative to healthy controls, the patient groups with MAPT mu-
tations, with TDP-C pathology and with FUS pathology had rela-
tively localized proﬁles of grey and white matter loss. In the MAPT
mutation group, grey matter loss was relatively symmetric be-
tween the cerebral hemispheres and most marked in medial and
anterior inferior temporal cortex with less marked involvement of
orbitofrontal cortex and insula; localized white matter loss was
Figure 2 Voxel-based morphometry analysis on grey matter regions in FTLD pathological groups relative to healthy controls. Statistical
parametric maps have been thresholded at P50.01 after false discovery rate correction over the whole-brain volume and rendered on
axial (left) and coronal (right) sections of a study-speciﬁc average group T1-weighted MRI template image in DARTEL space. The colour
bar (lower right) indicates the t-score. This analysis was performed on ﬂipped images (see text). For ease of comparison, the same brain
template sections are shown for each pathological group; co-ordinates (mm) for the plane of each section are indicated below.
aFTLDU = atypical FTLDU; CBD = corticobasal degeneration.
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and fornix. In the TDP-C group, there was asymmetric grey matter
loss predominantly involving the temporal poles and anterior
inferior temporal cortex with less marked involvement of
orbitofrontal cortex, insula and anterior cingulate; white matter
loss was evident predominantly in the region of the inferior lon-
gitudinal fasciculus, uncinate fasciculus and fornix. In the FUS
group, there was relatively symmetric grey matter loss
Figure 3 Voxel-based morphometry analysis on white matter regions in FTLD pathological groups relative to healthy controls. Statistical
parametric maps have been thresholded at P50.01 after false discovery rate correction over the whole-brain volume and rendered on
axial (left) and coronal (right) sections of a study-speciﬁc average group T1-weighted MRI template image in DARTEL space. The colour
bar (lower right) indicates the t-score. This analysis was performed on ﬂipped images (see text). For ease of comparison, the same brain
template sections are shown for each pathological group; co-ordinates (mm) for the plane of each section are indicated below.
CBD = corticobasal degeneration.
Table 3 Grey and white matter regions predominantly involved in voxel-based morphometry analysis of FTLD pathologies
Grey matter White matter
Frontal Temporal Parietal Subcortical
dFL ACC OFC sTL/Ins TP mTL iTL pTL PCC/PC LPL BG Thal SLF ILF UF CC Fornix Brainstem
Pick’s disease + + + + + + + + + + + + + + + + +
MAPT mutations + + + + + + +
Corticobasal degeneration + + + + + + + + +
TDP-A + + + + + + + + + + + + + + + +
TDP-C + + + + + + + + + +
FUS + + +
Involved regions (coded +) are based on the contrast between the disease group and healthy control subjects, at a voxel-wise signiﬁcance threshold P50.01 corrected
over the whole brain volume.
ACC = anterior cingulate cortex; BG = basal ganglia; CC = corpus callosum; dFL = dorsolateral frontal lobe; ILF = inferior longitudinal fasciculus; iTL = inferior temporal lobe;
Ins = insula; LPL = lateral parietal lobe; MAPT = microtubule-associated protein tau; mTL = medial temporal lobe; OFC = orbitofrontal cortex; PC = precuneus;
PCC = posterior cingulate cortex; pTL = posterior temporal lobe; SLF = superior longitudinal fasciculus; sTL = superior temporal lobe; TDP-A = TAR-DNA-binding protein-43
type A pathology; TDP-C = TAR-DNA-binding protein-43 type C pathology; Thal = thalamus; TP = temporal pole; UF = uncinate fasciculus.
2574 | Brain 2011: 134; 2565–2581 J. D. Rohrer et al.predominantly involving orbitofrontal cortex, insula and caudate
nuclei; there was no signiﬁcant white matter involvement.
More extensive proﬁles of tissue loss were evident in the patient
groups with Pick’s disease, corticobasal degeneration and TDP-A
pathology. In the Pick’s disease group, there was asymmetric grey
matter loss predominantly involving dorsolateral and orbitofrontal
cortex, insula, anterior temporal lobe, anterior cingulate, putamen
and thalamus, with less marked involvement of more posterior
temporal cortex, precuneus and anterior parietal cortex and caud-
ate; white matter loss predominantly occurred in the region of the
anterior inferior longitudinal fasciculus, superior longitudinal fascic-
ulus and corpus callosum. In the corticobasal degeneration group,
grey matter loss was relatively symmetric and most marked in the
dorsolateral frontal cortex, insula, superior temporal cortex, anter-
ior cingulate and caudate, with less marked involvement of pre-
cuneus and inferior parietal cortex; white matter loss was most
marked in the region of the superior longitudinal fasciculus and
inferior longitudinal fasciculus. In the TDP-A group, there was
asymmetric but extensive grey matter loss most markedly invol-
ving dorsolateral and orbitofrontal cortex, insula, anterior, middle
and inferior temporal cortex, anterior cingulate, thalamus and
caudate, with less marked involvement of precuneus and inferior
parietal cortex; there was associated extensive white matter loss in
the region of the superior longitudinal fasciculus, inferior longitu-
dinal fasciculus, corpus callosum and ﬁbre projection pathways via
the brainstem.
Post hoc cluster analysis
Whereas voxel-based morphometry can identify group-level dis-
ease signatures, it does not assess individual variation in neuro-
anatomical proﬁles within disease groups. Here we used a post
hoc hierarchical cluster analysis (Everitt et al., 2001; further details
in Supplementary Material) to further investigate the hypothesis
that the individuals comprising the FTLD cohort could be parti-
tioned using neuroanatomical proﬁles according to pathological
diagnosis. Motivated by the results of the voxel-based morphom-
etry analysis, for each subject we derived three measures based on
lobar grey matter volumes: a measure of the extent of frontal lobe
(extratemporal) versus temporal lobe involvement (the difference
between mean frontal and temporal lobe grey matter volumes,
each normalized to the corresponding control mean lobar grey
matter volume); a measure of inter temporal asymmetry (the
modulus of the difference between right and left temporal lobe
grey matter volumes, normalized to the control mean temporal
lobe grey matter volume); and a measure of inter-frontal asym-
metry (the modulus of the difference between right and left front-
al lobe grey matter volumes, normalized to the control mean
frontal lobe grey matter volume).
Cluster analyses based on each of these measures partitioned
the FTLD cohort into two subgroups (Fig. 4; details provided in
Supplementary Material); taken together, these analyses parti-
tioned the FTLD cohort into at least four pathological subgroups
(Pick’s, MAPT, TDP-C, corticobasal degeneration/FUS), in align-
ment with the group-level voxel-based morphometry ﬁndings
(Fig. 5). TDP-C pathology was consistently associated with focal,
asymmetric temporal lobe atrophy; MAPT mutations with focal
relatively symmetric temporal lobe atrophy; Pick’s disease with
asymmetric extra temporal atrophy; and corticobasal degeneration
and FUS pathology with relatively symmetric, extra temporal
atrophy. Pick’s disease cases showed the most variation in regional
atrophy proﬁle, a substantial proportion of cases showing
asymmetric temporal in addition to frontal lobe atrophy. There
was also substantial individual variation within the TDP-A group:
the majority of cases showed extratemporal atrophy; however, the
degree of asymmetry varied widely between individuals in this
group.
It is noteworthy that the difference measures were less useful
for differentiating cases on clinical syndromic rather than patho-
logical grounds: the inter temporal asymmetry measure separated
cases with semantic dementia from other syndromic groups (con-
sistent with the close association between semantic dementia and
TDP-C pathology), but the neuroimaging metrics used here did
not resolve the PNFA and behavioural variant FTD syndromic
groups (Fig. 4).
Discussion
Here we have presented clinical and neuroanatomical ﬁndings in a
large series of patients representing the major pathologies of the
FTLD spectrum. The ﬁndings underline the clinical, anatomical and
pathological heterogeneity of these diseases and corroborate the
evidence of previous pathological series (Hodges et al., 2004;
Kertesz et al., 2005; Forman et al., 2006; Josephs et al., 2006a,
b, 2008b, 2009; Snowden et al., 2007; Geser et al., 2009;
Whitwell et al., 2009b, d; Rohrer et al., 2010b). Convergent
neuroanatomical data from volumetric, voxel-based morphometry
and cluster analyses suggest a framework for classifying FTLD
pathologies according to their neuroanatomical atrophy proﬁles
across the brain: rather than regional anatomical or syndromic
associations, this framework (Fig. 5) is based on pathologically
determined network disintegration.
Clinical associations of frontotemporal
lobar degeneration pathologies
Considering the series ﬁrstly from a clinical perspective, certain
relatively speciﬁc clinicopathological associations were conﬁrmed:
semantic dementia with TDP-C pathology; FTD-MND with TDP-B
pathology; young-onset behavioural variant FTD with FUS path-
ology; and progressive supranuclear palsy syndrome with progres-
sive supranuclear palsy pathology. PNFA was most commonly
associated with tau pathologies, also in line with previous evidence
(Josephs et al., 2006a); this association may be more speciﬁc for
PNFA accompanied by speech apraxia, consistent with present
evidence that orofacial apraxia accompanies tau but not TDP
pathology. However, behavioural variant FTD (the most
common clinical syndrome across the present FTLD cohort) was
histopathologically heterogeneous. Similar diversity was evident
when considering the clinical associations of particular pathological
entities. Pick’s disease was clinically heterogeneous: though
3R-tau-deﬁned Pick’s disease has been relatively little studied,
this heterogeneity is in line with previously reported
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2005; Shi et al., 2005; Forman et al., 2006; Josephs et al.,
2006b; Llado ´ et al., 2008; Mesulam et al., 2008; Yokota et al.,
2009; summarized in Supplementary Table 6). Our series reafﬁrms
the clinical heterogeneity of corticobasal degeneration (Tang-Wai
et al., 2003; Murray et al., 2007; Josephs and Duffy, 2008a;
Vanvoorst et al., 2008; Ling et al., 2010). The clinical features
of TDP-A pathology in our series were similar whether or not
associated with a GRN mutation (see Supplementary Table 5).
Neuroanatomical associations of
frontotemporal lobar degeneration
pathologies
No single cortical or subcortical region was speciﬁcally involved in
association with a particular pathological process. However, patho-
logical groups varied substantially in the hemispheric distribution
of atrophy. This variation was evident at group level, in a quan-
titative volumetric analysis of preselected brain regions (Table 2)
and in a qualitative but unbiased comparison of atrophy proﬁles
(using voxel-based morphometry, Table 3); and after taking
individual variation into account, in a cluster analysis (Fig. 4). In
particular, the pathological groups here segregated according to
whether they were associated with relatively symmetric versus
strongly asymmetric involvement of the cerebral hemispheres
(Table 2, Figs 1 and 4), and whether they were associated with
relatively localized temporal versus extra temporal atrophy within
an affected hemisphere (Table 3, Figs 2–4).
Considering ﬁrstly the relative degree of cerebral asymmetry
(the more directly quantiﬁable factor), MAPT mutations, cortico-
basal degeneration and FUS pathology were each associated at
group level with relatively symmetric hemispheric atrophy;
whereas Pick’s disease, TDP-A and TDP-C pathology were each
associated at group level with strongly asymmetric hemispheric
atrophy. In addition to the extent of cerebral asymmetry, FTLD
pathologies here could be grouped according to the extent of
intra-hemispheric atrophy. MAPT mutations and TDP-C pathology
each produced a relatively localized proﬁle of atrophy maximally
affecting the temporal lobes. MAPT mutations were associated
with anteromesial temporal lobe atrophy; while there is a need
for caution in attributing a common voxel-based morphometry
proﬁle to MAPT mutations considered as a group (Whitwell
et al., 2009a), case numbers here as in previous single-centre
Figure 4 Cluster analyses of the FTLD cohort. Cluster analyses are shown for pathological (right-hand text column for each panel) and
clinical syndromic diagnoses, according to frontotemporal, intertemporal and interfrontal volumetric difference measures (see text).
Cluster dendrograms use average linkage between groups. Each cluster dendrogram demonstrates separation of the entire FTLD group
into two subgroups based on the corresponding difference measure; together, the measures partition the cohort into at least four
pathological subgroups (Pick’s, MAPT, TDP-C, corticobasal degeneration/FUS; Fig. 5). bvFTD = behavioural variant FTD;
CBD = corticobasal degeneration; PSPS = progressive supranuclear palsy syndrome; SD = semantic dementia.
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speciﬁc analysis. These ﬁndings are consistent with previous
neuroanatomical evidence from other series (Josephs et al.,
2009; Pereira et al., 2009; Whitwell et al., 2009a, b). In contrast,
Pick’s disease, TDP-A and corticobasal degeneration pathology
each produced widespread atrophy of cortical and subcortical re-
gions and their connections. The atrophy proﬁles in these diseases
overlapped extensively in frontal, temporal, parietal and subcor-
tical areas within an affected hemisphere. These ﬁndings are in
keeping with other neuroanatomical evidence for pathologically
deﬁned Pick’s disease (Whitwell et al., 2009b, 2011), TDP-A path-
ology (Rohrer et al., 2010b; Whitwell et al., 2011) and corticoba-
sal degeneration (Josephs et al., 2008b, 2010; Whitwell et al.,
2011). The wide variation in individual proﬁles within the TDP-A
group (Figs 1 and 4) suggests that other factors (for example, the
presence of a GRN mutation) may modulate the macro-anatomical
expression of TDP-A. Corticobasal degeneration is often con-
sidered an asymmetric disease on clinical and neuropsychological
grounds; however, quantitative studies of atrophy in pathologically
proven corticobasal degeneration have not demonstrated striking
hemispheric asymmetry; a previous voxel-based morphometry
study (Josephs et al., 2008b) demonstrated distributed frontopar-
ietal cortical, insula, posterior temporal and caudate involvement
similar to the present ﬁndings. FUS pathology here involved pre-
dominantly extratemporal fronto-subcortical circuitry (including, in
particular, the caudate nuclei) but with a relatively localized and
symmetrical distribution; this is consistent with limited previous
evidence (Josephs et al., 2010).
Considering these neuroanatomical data together, we propose
that FTLD-associated pathologies can be segregated based on
their cerebral atrophy proﬁles, according to the following
scheme: asymmetric, relatively localized (predominantly temporal
lobe) atrophy (TDP-C); relatively symmetric, relatively localized
(predominantly temporal lobe) atrophy (MAPT mutations); strong-
ly asymmetric, distributed atrophy (Pick’s, TDP-A); and relatively
symmetric, predominantly extratemporal atrophy, which may be
either distributed (corticobasal degeneration) or relatively localized
(FUS).
Network signatures of frontotemporal
lobar degeneration pathology: a
clinico-anatomical formulation
If indeed tissue pathologies within the FTLD spectrum have sep-
arable neuroanatomical signatures, how can this be reconciled
with the extensive clinical and anatomical overlap among these
diseases, which was evident here as in most previous series
(Pereira et al., 2009; Weintraub and Mesulam, 2009; Whitwell
et al., 2009b, c)? There are at least two complementary
clinico-anatomical formulations that might potentially reconcile
clinical heterogeneity with relative anatomical speciﬁcity. First,
the canonical FTLD clinical syndromes of behavioural variant
FTD and PNFA both involve multi-component cognitive functions:
clinical similarities might therefore arise from quite distinct patho-
physiological and neuroanatomical mechanisms; and indeed, the
syndromes of behavioural variant FTD and PNFA in this series
were associated with substantial clinical and anatomical hetero-
geneity (Supplementary Tables 2 and 4), supporting previous for-
mulations (Josephs et al., 2006a, 2009; Whitwell et al., 2009b).
Secondly, the pathological processes associated with these syn-
dromes tend to involve distributed hemispheric areas and their
connections. A disease process beginning in one region of the
hemisphere might produce a clinical syndrome distinct from that
produced by the same disease process beginning in another,
remote cerebral region; initial involvement of the right frontal
lobe (irrespective of the pathological process) may be more likely
to present as behavioural variant FTD, initial involvement of left
frontal cortex as PNFA and initial involvement of more posterior
cortices as corticobasal syndrome. If, however, pathological pro-
cesses evolve in an anatomically restricted manner, then conver-
gence of clinical syndromes should occur in a predictable sequence
over time. Such a clinico-anatomical convergence would be con-
sistent with previous evidence (in, for example, corticobasal de-
generation and Pick’s disease: Kertesz et al., 2005; Sanchez-Valle
et al., 2006; Geda et al., 2007; Yokota et al., 2009; Rogalski
et al., 2011) and also with the present data. This interpretation
allows for ﬁne-grained clinical and anatomical differentiation
within a broad syndrome category, according to the underlying
pathological process (Supplementary Tables 2–4); for example, the
present ﬁndings suggest that semantic dementia variants may be
clinically and anatomically differentiable.
The synthesis we present here is compatible with previous evi-
dence for differentiable neuroanatomical associations of FTLD
pathologies (Josephs et al., 2009; Whitwell et al., 2009a, b,
2011; Rohrer et al., 2010b). Here, we extend this synthesis
across the breadth of the FTLD spectrum, taking into account
Figure 5 Diagrammatic summary of neuroanatomical features
associated with pathological diagnosis in this FTLD cohort. The
ﬁgure is based on volumetric, voxel-based morphometry and
cluster analyses of the present neuroimaging data. Diseases can
in general be classiﬁed according to whether they produced
relatively focal temporal lobe atrophy (TL) or atrophy
predominantly involving extratemporal (extra-TL; e.g. frontal
lobe) regions; and according to whether they produced relatively
symmetric or strongly asymmetric atrophy. Pick’s disease was
associated with an asymmetric atrophy proﬁle variably involving
temporal or extra temporal regions. TDP-A was associated with
strongly asymmetric atrophy (especially in association with GRN
mutations) but with wide individual variability.
CBD = corticobasal degeneration.
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rather than broad groupings such as FTLD-tau or FTLD-TDP.
We do not claim that particular FTLD pathologies show speciﬁcity
for a particular brain region: rather, we argue that speciﬁcity
emerges as a proﬁle of involvement across multiple anatomical
regions. It is increasingly recognized that neurodegenerative dis-
eases target large-scale neural networks that have an intrinsic con-
nectivity laid down in the healthy brain (Seeley et al., 2009). It is
known that Alzheimer’s disease and non-Alzheimer pathologies
target distinct cerebral networks (Zhou et al., 2010); however,
most previous correlative studies of network breakdown in FTLD
have focused on syndromes rather than histopathological sub-
strates. Thus, the behavioural variant FTD syndrome implicates
an anterior fronto-subcortical network that mediates goal-directed
social behaviours (Seeley et al., 2007). In contrast, the syndromes
of PNFA and semantic dementia implicate dominant hemispheric
dorsal fronto-insulo-parietal and anterior temporo-ventrofrontal
networks mediating aspects of language output and comprehen-
sion, respectively (Saur et al., 2008; Seeley et al., 2009). Each of
these networks was implicated (to a variable degree) by the spec-
trum of FTLD pathologies in the present series (Figs 2 and 3,
Table 3): the anterior fronto-subcortical network particularly with
Pick’s, corticobasal degeneration, TDP-A and FUS pathology; the
dorsal fronto-insulo-parietal network with Pick’s, corticobasal
degeneration and TDP-A pathology; and the anterior
temporo-ventrofrontal network with TDP-C, Pick’s, MAPT and
TDP-A pathology. However, the neuroanatomical framework we
propose here primarily addresses pathology rather than clinical
syndrome; we argue that any account of neural network degen-
eration must ultimately take the underlying pathological substrate
into account. Since clinical syndromes are associated with involve-
ment of particular brain networks (Seeley et al., 2009) and since
particular pathologies often produce more than one clinical syn-
drome (Table 1, Supplementary Tables 2–4), in general the effects
of a particular pathological substrate will be expressed in more
than one functional network (though there may be important
exceptions; for example, the effects of TDP-C may be largely
restricted to a single anterior temporo-ventrofrontal network).
We propose that pathologies in the FTLD spectrum target dis-
tributed brain networks in a predictable manner. Speciﬁcally, we
propose that the pattern of network disintegration in these dis-
eases is determined by the interaction of at least two key factors:
the distribution of the disease interhemispherically, and the distri-
bution of the disease within a hemisphere. These factors could, in
principle, operate over any individual brain region or brain net-
work; together, however, they tend to constrain the
macro-anatomical proﬁle of the disease. According to this formu-
lation, the neuroanatomical speciﬁcity of these diseases is likely
primarily to reﬂect underlying network morphology (the charac-
teristics of the ﬁbre tracts and synaptic connections that compose
the network, and allow disease spread). The local mechanisms that
translate molecular lesions to neural network dysfunction remain
largely unknown; however, candidate mechanisms are likely to
include loss of regulatory or trophic factor support acting on syn-
apses or glial structures, propagation of toxic molecules and
disturbed network homeostasis (Seeley, 2008, 2009). The micro-
scopic organization of a neural network could confer relative
vulnerability or resistance to such mechanisms; the macroscopic
expression of the pathological process would then depend on
interaction of the causative lesion with critical network elements.
For example, the large projection neurons of Von Economo that
mediate focal network disintegration underpinning behavioural
variant FTD are vulnerable to both tau and TDP-43 pathology
but apparently resistant to Alzheimer pathology (Seeley, 2008),
while GRN-associated TDP-43 inclusions have been shown to
target the dominant hemispheric language network in a stereolo-
gical analysis (Gliebus et al., 2010). The two-factor (cerebral
asymmetry, hemispheric contiguity) classiﬁcation of FTLD patho-
logical signatures that we propose here is likely to be an
oversimpliﬁcation; however, certain molecular and network char-
acteristics have been identiﬁed that could potentially interact to
produce a fundamentally dichotomous partition of this kind.
Examples include the dichotomy between toxic gain and loss of
function among the spectrum of molecular insults causing FTLD
(Winklhofer et al., 2008); and the dichotomy between long-range
and short-range pathways in the organization of cortical networks
(Sporns and Zwi, 2004).
Future directions
This study has several important limitations that suggest directions
for future work. Opportunities for anatomical and pathological
correlation in less common FTLD syndromes are limited, and
case numbers in this (as in previous) series were relatively small.
This factor indicates a need for caution when interpreting statis-
tical effects, limiting the power of the study to identify effects and
potentially increasing susceptibility to ascertainment bias. This
might in turn account for the absence or scarcity of certain
FTLD phenotypes here [e.g. Alzheimer-like (Kelley et al., 2009,
2010) and FTD-MND syndromes]. The study was retrospective;
accordingly, neuropsychological functions could not be systemat-
ically assessed using a uniform battery. Appropriately directed and
detailed neuropsychological assessment might corroborate or ad-
vance the framework suggested by neuroimaging data. Finally, the
identiﬁcation of a clinico-anatomical signature does not resolve the
mechanism by which a particular pathological process gives rise to
that signature; to deﬁne such mechanisms will require an under-
standing of how molecular and cellular pathophysiology acts on
local neural circuitry and how local molecular processes scale up to
the level of large-scale networks.
The present ﬁndings underline the need for further detailed,
prospective longitudinal studies correlating tissue pathology with
clinical, neuropsychological and neuroimaging features in large
(ideally, multi-centre), pathologically conﬁrmed FTLD series. Such
studies should include connectivity-based methods such as diffu-
sion tensor tractography and resting-state functional MRI that can
delineate neural networks empirically (Seeley et al., 2009;
Acosta-Cabronero et al., 2011), complementing computational
modelling (Fletcher and Warren, 2011) and micro-physiological
(Winklhofer et al., 2008) approaches. Detailed regional histomor-
phometry will be an essential link between these levels of descrip-
tion (Davies et al., 2005; Gliebus et al., 2010; Piguet et al., 2011),
by directly assessing the propensity of pathological processes to
spread via local and connected neural elements and establishing
2578 | Brain 2011: 134; 2565–2581 J. D. Rohrer et al.the cytoarchitectural boundaries of these processes. In order to
substantiate molecular speciﬁcities, anatomical associations of par-
ticular pathologies should be sought within as well as between
broad syndromic categories such as behavioural variant FTD
(Whitwell et al., 2009b). There is a particular need for longitudinal
tracking of clinical and neuroanatomical patterns of disease evo-
lution, to assess the extent to which syndromes transform over
time and the precise sequence of such transformations. If indeed
particular pathologies manifest in speciﬁc proﬁles of network dis-
integration, then longitudinal clinico-anatomical proﬁles are likely
to be at least as informative as cross-sectional signatures (Whitwell
et al., 2009c; Rogalski et al., 2011), and would provide a direct
test of the hypotheses advanced here.
From a clinical perspective, we do not argue that the identiﬁ-
cation of group-level signatures of tissue pathology will necessarily
allow accurate prediction of pathology in the individual patient.
Rather, we anticipate that such signatures will suggest new
network-level biomarkers and perhaps disease mechanisms. This
in turn could help direct clinical trials targeting particular tissue
pathologies. If distinctive clinico-anatomical signatures of FTLD
pathologies can be substantiated, this would constrain the
modus operandi governing how pathological processes are ex-
pressed in the brain: we see this as an important ﬁrst step towards
a molecular physiology of FTLD.
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